Summary:
Aurobindo Pharma USA has secured FTC approval for its $250 million acquisition of Lannett Company LLC. The deal strengthens Aurobindo’s presence in the U.S. pharmaceutical market through expanded manufacturing capacity and a broader complex generics portfolio. The acquisition is expected to be earnings accretive and support long-term growth through operational synergies.
Aurobindo Pharma USA, Inc., a wholly owned subsidiary of Aurobindo Pharma Limited, announced on June 22, 2026, that it has received approval from the U.S. Federal Trade Commission (FTC) to go ahead with its acquisition of Lannett Company LLC. The transaction is valued at $250 million on a cash-free, debt-free basis, inclusive of normalised working capital, and is expected to close before the end of June 2026.
Who Is Lannett Company?
Lannett Company LLC is a Pennsylvania-based generic pharmaceutical company with a specific focus on complex, non-opioid controlled substances. The company develops and commercialises a diversified portfolio of such products, which sit in a segment of the generics market that requires more technical expertise and regulatory rigour than standard formulations.
Lannett operates a manufacturing site in Seymour, Indiana, which has the capacity to produce approximately 4 billion doses annually. That scale of domestic manufacturing is significant, particularly in the context of ongoing U.S. policy discussions around pharmaceutical supply chain resilience and reducing dependence on overseas production.
What Does This Acquisition Bring to Aurobindo?
The deal adds several things to Aurobindo USA's existing business. Most directly, it expands the company's product portfolio in the complex generics and controlled substances space, a segment where barriers to entry are higher and competition is relatively more limited than in standard generic formulations.
The Seymour, Indiana facility also adds a U.S.-based manufacturing footprint to Aurobindo USA's network. This matters because U.S. regulators and policymakers have been placing increasing emphasis on domestic pharmaceutical manufacturing capacity. Having production on U.S. soil aligns with those priorities and could prove useful from a regulatory and commercial standpoint going forward.
From a financial perspective, the acquisition is expected to be immediately accretive to Aurobindo Group's earnings per share, meaning it should add to profitability from the moment the deal closes, rather than taking time to contribute. The company also anticipates cost efficiencies, savings in selling, general and administrative (SG&A) expenses, and operational integration benefits over time.
Management Commentary
Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA, said the acquisition represents a compelling strategic and financial opportunity. "It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances. We are confident it will deliver immediate earnings accretion while creating long-term value for our shareholders through operational synergies and pipeline expansion," he said.
Tim Crew, Chief Executive Officer of Lannett Company, welcomed the development. "As one of the nation's oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines. Aurobindo's market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere," he said.
Aurobindo Pharma Share Price
Aurobindo Pharma share price was trading at ₹1,483.50, as of 11:35 AM on June 22, 2026, down 0.95% for the day. The stock touched an intraday high of ₹1,511.00 and a low of ₹1,480.50. Trading volume stood at 9.18 lakh shares compared with the 30-day average volume of 13.30 lakh shares.
About Aurobindo Pharma
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercialises a wide range of generic pharmaceuticals, branded specialty products, and active pharmaceutical ingredients across more than 150 countries.
The company operates over 30 manufacturing and packaging facilities, all approved by leading regulatory bodies including the USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA. Its product portfolio spans seven therapeutic areas: CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics, and Anti-Allergic, supported by an in-house R&D setup.
Aurobindo Pharma USA, the acquiring entity in this transaction, focuses on the development, manufacturing, and commercialisation of generic and specialty pharmaceutical products in the U.S. market.
Conclusion
The final regulatory clearance received by Aurobindo Pharma USA through the FTC approval for the $250 million purchase of Lannett Company LLC removes the last hurdle to be overcome for the completion of the transaction before June 2026. This business acquisition will provide the company with a manufacturing unit in the U.S. capable of producing 4 billion doses annually. It will increase the company's range of generics as well as controlled substances. It is anticipated that this will make positive contributions to the company's earnings right from the first day.
